𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Initial treatment of early Parkinson’s disease: A review of recent, randomized controlled trials

✍ Scribed by Kevin Biglan; Robert G. Holloway

Book ID
107543119
Publisher
Springer
Year
2001
Tongue
English
Weight
330 KB
Volume
1
Category
Article
ISSN
1528-4042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Double-blind, randomized, controlled tri
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
✍ Matthew B. Stern; Kenneth L. Marek; Joseph Friedman; Robert A. Hauser; Peter A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 2 views

## Abstract Rasagiline (__N__‐propargyl‐1(__R__)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients n

Twice-daily, low-dose pramipexole in ear
Twice-daily, low-dose pramipexole in early Parkinson's disease: A randomized, placebo-controlled trial
✍ Karl Kieburtz; The Parkinson Study Group PramiBID Investigators 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

## Abstract To compare the safety and efficacy of low dosages of pramipexole given twice daily (bid) in early Parkinson's disease (PD) with those of a standard 3 times daily (tid) regimen in a randomized, double‐blind, placebo controlled trial involving 311 early PD patients not receiving dopaminer

A randomized, double-blind trial of tran
A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease
✍ Holly A. Shill; Sanja Obradov; Yakov Katsnelson; Ray Pizinger 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty‐three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unif